Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Pia Burman

Physician

Default user image.

Low-dose GH improves exercise capacity in adults with GH deficiency: effects of a 22-month placebo-controlled, crossover trial

Author

  • J Bollerslev
  • J Hallen
  • KJ Fougner
  • AP Jorgensen
  • C Kristo
  • H Fagertun
  • O Gudmundsen
  • Pia Burman
  • T Schreiner

Summary, in English

Fifty-five patients with adult-onset GH deficiency (mean age, 49 years) were enrolled in a placebo-controlled, crossover study to investigate the effects of GH therapy on exercise capacity, body composition, and quality of life QOL). GH and placebo were administered for 9 months each, separated, by a 4-month washout period. GH therapy was individually dosed to obtain an IGF-I concentration within the normal range for age and sex. The final mean daily dose of GH was 1.2 IU/day for men and 1.8 IU/day for women. Mean lGF-I concentration at baseline was higher in men than in women(9 95 +/- 33 vs 68 +/- 41 mu g/l respectively; P < 0.04) and increased to a similar level on GH therapy. Body fat mass was reduced by 1.9 +/- 2.9 kg and lean body mass was increased by 1.8 +/- 2.8 kg (P = 0.0001 for each) with GH treatment. Total and low-density cholesterol levels decreased. Absolute maximal oxygen uptake increased by 6% (P = 0.01), relative to body weight by 9% (P = 0.004), and there was a trend toward increased endurance performance by 7% (P = 0.07). There were no significant effects on QOL. In conclusion, treatment with a low, physiologic dose of GH produced positive effects on body composition and lipids and improved exercise capacity, likely to be of clinical relevance. No changes in QOL were seen, possibly because of a good QOL at baseline.

Department/s

  • Genomics, Diabetes and Endocrinology

Publishing year

2005

Language

English

Pages

379-387

Publication/Series

European Journal of Endocrinology

Volume

153

Issue

3

Document type

Journal article

Publisher

Society of the European Journal of Endocrinology

Topic

  • Endocrinology and Diabetes

Status

Published

Research group

  • Genomics, Diabetes and Endocrinology

ISBN/ISSN/Other

  • ISSN: 1479-683X